On Monday, CF Industries Holdings, Inc. (NYSE:CF)’s shares inclined 1.50% to $64.19.
CF Industries Holdings, Inc. (CF) disclosed that its Board of Directors has elected Anne P. Noonan as an independent director of the company. Ms. Noonan, president, Performance Chemicals Business Segment at OMNOVA Solutions, is expected to stand for re-election by stockholders at the company’s 2016 Annual Meeting. Her election brings membership of the CF Industries Holdings, Inc. Board of Directors to ten.
CF Industries Holdings, Inc. manufactures and distributes nitrogen fertilizers and other nitrogen products worldwide. The company’s principal nitrogen fertilizer products comprise ammonia, granular urea, and urea ammonium nitrate solution. Its other nitrogen products comprise ammonium nitrate, diesel exhaust fluid, urea liquor, and aqua ammonia. The company offers its products primarily to cooperatives, independent fertilizer distributors, and industrial users.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares gained 1.14% to $8.87.
Ariad Pharmaceuticals, Inc. (ARIA) declared long-term follow up from its pivotal Phase 2 trial of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of about 3.5 years for chronic phase CML (CP-CML) patients and a median follow-up of about 2.9 years in all patients in the trial, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options. Responses have been maintained long-term in CP-CML patients. Eighty-three percent (83%) of CP-CML patients who achieved a major cytogenetic response (MCyR) are estimated to remain in MCyR at three years.
Additionally, 95 percent of CP-CML patients who underwent ponatinib dose reductions maintained their responses (MCyR). Benefit-risk evaluations should guide the decision to initiate and maintain Iclusig therapy, particularly in patients who may be at raised risk for arterial occlusive events (AOE).
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories. It also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, an orally active TKI for treating non-small cell lung cancer and various other solid tumors.
At the end of Mondays trade, Anadarko Petroleum Corporation (NYSE:APC)‘s shares surged 0.16% to $81.95.
Anadarko Petroleum Corporation (APC) accomplished its formerly declared public offering and sale of 8,000,000 7.50% tangible equity units (the “Units”) at a public offering price of $50.00 per Unit, following a Terms Agreement, dated as of June 4, 2015 (counting the Underwriting Agreement (Standard Provisions) incorporated therein, the “Terms Agreement”), among the Company, Western Gas Equity Partners, LP (“WGP”), Western Gas Equity Holdings, LLC and J.P. Morgan Securities LLC, as representative of the other underwriters named therein. Following the Terms Agreement, the Company has also granted the underwriters a 30-day option to purchase up to an additional 1,200,000 Units at the same price.
The sale of the Units was made following the Company’s Registration Statement on Form S-3, as amended (Registration No. 333-192219), counting a prospectus supplement dated June 4, 2015 (the “Prospectus Supplement”) to the prospectus contained therein dated June 3, 2015, filed by the Company with the Securities and Exchange Commission, following Rule 424(b)(5) under the Securities Act of 1933, as amended.
Anadarko Petroleum Corporation engages in the exploration, development, production, and marketing of oil and gas properties. It operates through three segments: Oil and Gas Exploration and Production; Midstream; and Marketing. The Oil and Gas Exploration and Production segment explores for and produces natural gas, oil, condensate, and natural gas liquids (NGLs).
Zillow Group Inc (NASDAQ:Z), ended its Monday’s trading session with -0.65% loss, and closed at $90.18.
Zillow Group Inc (Z) which houses a portfolio of the largest and most vibrant real estate and home-related brands on mobile and Web, recently declared the pending sale of ActiveRain®, a social networking, blogging, and training platform for the real estate industry, to the Ben Kinney family of companies. The sale is predictable to close June 30, 2015.
Zillow Group, Inc. operates real estate and home-related information marketplaces on mobile and the Web in the United States. It offers a portfolio of brands and products to assist people find vital information about homes, and connect with local professionals. The company product portfolio comprises Zillow, a real estate and rental marketplace dedicated to consumers with data, inspiration, and knowledge around the place they call home, and connecting them with the local professionals who can assist; and Trulia, a home shopping marketplace, focused on giving home buyers, sellers, and renters the information they need to make better decisions about where to live.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
